BWAY Brainsway

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:Tuesday, November 12, 2024
Time:8:30 AM Eastern Time
United States:1-877-300-8521
International:1-412-317-6026
Israel:1-80-921-2373
Conference ID:10193781
Webcast:

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, . Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Contacts:

BrainsWay:

Ido Marom

Chief Financial Officer

Investors:

Brian Ritchie

LifeSci Advisors



EN
29/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life S...

BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY. Please contact your Citi representative to request a meeting at the conference. About BrainsWayBrainsWay is a g...

 PRESS RELEASE

BrainsWay Announces New Minority-Stake Investment in Canadian Provider...

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc. BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health...

 PRESS RELEASE

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Pri...

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent  issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magn...

 PRESS RELEASE

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors BURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that its Board of Directors approved a plan to change to the ratio of its American Depositary Shares (ADSs) listed on the Nasdaq Capital Market (...

 PRESS RELEASE

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerat...

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™ New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Highmark Blue Cross Blue Shield®, a company with over seven million covered lives that primarily serves Pennsylvania, Delaware, West Virginia, and parts of New York, has ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch